Feds recommend pausing vaccine for mosquito-borne disease chikungunya in people over 60
Federal drug safety officials have recommended pausing the use of a vaccine for a mosquito-borne disease known as chikungunya for people over 60 following reports of serious adverse events.
The U.S. Food and Drug Administration said that 17 serious adverse events, including two that resulted in death, have been reported in worldwide recipients of the vaccine Ixchiq over the age of 60. Six of the events occurred in the United States, the FDA said in a safety communication on Monday, May 12.
Domestic and global cases have been reported to the Vaccine Adverse Event Reporting System, run by the FDA and the U.S. Centers for Disease Control to flag potential safety problems with vaccines. The reported cases were in individuals with underlying chronic medical conditions and the adverse events "may not be causally related to vaccination," the FDA said.
The vaccine's maker, Valneva, said in a statement that it is "upholding the highest safety standards" and pointed to the potential for underlying conditions and other medications as contributing factors in the adverse events.
"Thorough evaluation of these cases is critical to ensure the safe use of Ixchiq," the company said.
French drug regulators updated their recommendations for Ixchiq in April and the European Medicines Agency announced that its safety committee had launched a review of the vaccine earlier this month and prohibited its use in people 65 and older, according to the Center for Infectious Disease Research and Policy at the University of Minnesota.
Chikungunya is a mosquito-borne illness named for the joint pain it causes, according to the Cleveland Clinic.
Most people infected by a mosquito bite recover from the illness in about one week, but some have lasting joint pain – the clinic says. There is no cure for the disease and treatment focuses on managing symptoms inlcuding:
The FDA approved Ixchiq for the prevention of the disease in adults over 18 in November 2023. It uses a live, though weakened, version of the virus that may cause symptoms similar to the disease, according to the FDA.
The FDA said that some of the reported adverse events were consistent with severe complications of chikungunya disease.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Sanofi (SNY) Takes Bold $9.5Bn Immunology Leap
Sanofi (SNY) has its hands full—in the best way possible—after announcing its $9.5 billion acquisition of Blueprint Medicines. This marks the French pharma giant's fourth major strategic acquisition this year, but this deal stands out. Sanofi isn't just picking up a drug or two; it's gaining access to a robust immunology pipeline of internally developed therapies. In addition to securing Ayvakit, a treatment for systemic mastocytosis, the acquisition reinforces Sanofi's shift toward high-value biopharma assets. Despite recent stock underperformance, this bold move strengthens my long-term bullish outlook on Sanofi. Confident Investing Starts Here: Sanofi's Strategic Pivot Towards High-Value Biopharma Sanofi's recent sale of Opella, its consumer healthcare division, highlights a broader strategic shift toward prioritizing high-margin biopharma operations. The company has seen major success with Dupixent—a blockbuster drug for inflammatory conditions like COPD and dermatitis, which generated over $13 billion in sales last year and now makes up nearly 30% of Sanofi's total revenue. This move underscores Sanofi's commitment to doubling down on its most profitable and innovative drug assets. Immediate Ayvakit Revenue Sanofi's acquisition of Blueprint, while a sizable investment, brings immediate benefits in both revenue diversification and pipeline strength. Ayvakit, approved for treating advanced systemic mastocytosis (AdvSM) in 2021 and indolent systemic mastocytosis (ISM) in 2023, addresses a rare disease with few treatment options. The drug generated $479 million in 2024, and Blueprint projected up to $720 million in revenue for 2025. With peak annual sales expected to reach around $2 billion before 2030, Ayvakit offers Sanofi a strong, near-term revenue driver, helping to de-risk the $9.1 billion upfront cost. Strategically, it's also a seamless addition to Sanofi's growing immunology portfolio. Boosting Sanofi's Immunology Future with Blueprint's Pipeline While Blueprint's pipeline includes several candidates, the spotlight is on two key assets: elenestinib and BLU-808. Elenestinib is a next-generation KIT D816V inhibitor currently in late-stage development for systemic mastocytosis (SM). It aims to improve upon the safety profile of Ayvakit, potentially appealing to patients who may avoid Ayvakit due to side effects such as fatigue and cognitive impairment, thereby expanding Sanofi's market share in SM. BLU-808, on the other hand, is an early-stage asset targeting a broader range of inflammatory conditions, including allergic asthma and allergic rhinoconjunctivitis. Unlike SM, these are far more prevalent diseases, offering significantly larger commercial opportunities. Importantly, BLU-808 is tied to two contingent value rights (CVRs), which are dependent on achieving specific development and regulatory milestones. These CVRs provide a layer of downside protection for Sanofi—if BLU-808 fails in clinical trials, the company's overall payout for the asset is reduced. Navigating Margin Pressures with Strategic Investment All of this comes against the backdrop of ongoing margin pressures for Sanofi. The company has already walked back its 2025 operating margin target of 32%, citing pricing pressures in its legacy general medicines segment and a ramp-up in R&D spending. While Sanofi remains active in diabetes with drugs like Lantus and Toujeo, these products now face significant pricing headwinds from generics, making them far less profitable than they once were. The Blueprint acquisition underscores Sanofi's renewed focus on innovation and high-margin biopharma assets. Though this pivot comes at the cost of near-term margin dilution, it reflects a longer-term strategy: investing in R&D today in hopes of developing the next wave of blockbuster therapies. In this context, Sanofi is clearly still in the midst of a strategic transformation—one currently anchored by the strong performance of Dupixent. Unlike previous 'bolt-on' deals that added just a drug or two, the Blueprint acquisition marks a more decisive step toward reshaping Sanofi's portfolio around premium, next-generation therapeutics. What is the Price Prediction for SNY Stock? On Wall Street, SNY sports a consensus Moderate Buy rating based on two Buy, three Hold, and zero Sell ratings in the past three months. Sanofi's average stock price target of $62.20 implies ~25% upside potential over the next 12 months. Last week, analyst Sachin Jain from Bank of America Securities maintained a Buy rating on SNY. The analyst was bullish on Sanofi's pipeline, particularly itepekimab, despite it failing in one of two Phase 3 trials for COPD. Moreover, he noted that 'Sanofi's low price-to-earnings ratio, reflecting limited pipeline upside, is seen as an opportunity given the promising data from these trials, indicating a potential R&D turnaround for the company.' Blueprint Deal Seals the Verdict on SNY In summary, Sanofi's acquisition of Blueprint offers both near-term revenue and long-term growth potential. Ayvakit serves as a valuable bolt-on asset, while pipeline candidates like elenestinib and BLU-808 significantly enhance Sanofi's immunology portfolio. More importantly, the deal reflects Sanofi's strategic pivot toward higher-margin biopharma assets at a time when older drugs like Lantus are facing profitability headwinds. Though the investment may pressure margins in the short run, it sets the stage for long-term growth in a high-value segment of the pharmaceutical market. Notably, the deal is expected to be EPS accretive by 2027, thanks to Ayvakit's revenue potential, which will help justify and offset a large portion of the upfront $9.5 billion cost. Overall, Sanofi has secured a promising set of assets at a reasonable valuation while extending its leadership in immunology beyond Dupixent. With a modest P/E ratio of 20.5 and a solid 3.27% dividend yield, SNY stands out as a compelling long-term investment opportunity for investors seeking to tap into the expanding biopharmaceutical space.
Yahoo
3 hours ago
- Yahoo
Marc Garneau died after 'short but very difficult battle' with cancer, former staffer says
Marc Garneau died this week after being diagnosed with two types of cancer earlier this year, his former staffer says. The first Canadian to travel to space and former cabinet minister died on Wednesday. He was 76. Marc Roy, Garneau's former chief of staff, told CBC's Power & Politicsthat the former minister had been diagnosed with lymphoma and leukemia earlier this year. "He fought a short but very difficult battle with two very rare types of cancer," Roy told host David Cochrane. "Although his diagnosis was only a couple of months ago, he was well until four or five weeks ago. So it went very, very quickly … it's a very, very tough loss." Roy said Garneau only shared his diagnosis with a small circle that agreed to respect his wish for privacy. "[It was] something he wanted to keep with his family so he could concentrate on his time with his family and not distract his family by the attention it could have gotten," Roy said. WATCH | It's a tragic loss,' says former chief of staff: Beyond his legacy as an astronaut, Garneau held a number of federal cabinet positions since 2015, including in transport and foreign affairs. Roy said Garneau was "tremendous" to work for as he reflected on his time in politics. "It's a huge loss to government. I think that his years in Ottawa are filled with many contributions to improving safety and expanding policy. I think he will be remembered for that for decades to come," Roy said. The House of Commons held another moment of silence for Garneau on Thursday and MPs took time to pay tribute to their former colleague. "He reminded us that Canadians can dream big, that we could aim for the stars quite literally," Government House leader Steve MacKinnon said. "He became a powerful symbol of the achievement and the accomplishment of this great country of ours." Like MacKinnon, other MPs reflected on how Garneau inspired Canadians. "Mr. Garneau, the future will always be inspired by your life, which was so inspiring for all Canadians," Conservative MP Gérard Deltell said in French. WATCH | Garneau's 'extraordinary ride': Bloc Québécois MP Rhéal Fortin said Garneau paved the way for other Canadians to journey to space, including Chris Hadfield and Julie Payette. "He showed us the way to the stars," Fortin said in French. Fighting back tears, Green Party Leader Elizabeth May said it was hard to say goodbye to "someone who was unfailingly kind [and] unfailingly respectful." "We've lost a very great human being, and to his entire family: my deepest condolences and sympathy — and know that in that space where he looks down at planet Earth now, I think it's a place called heaven."
Yahoo
4 hours ago
- Yahoo
YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)
SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for YOLT-101, an in vivo base editing therapy targeting PCSK9 for the treatment of heterozygous familial hypercholesterolemia (HeFH). "The FDA IND clearance marks a significant milestone for YolTech," said Dr. Yuxuan Wu, Co-founder and CEO of YolTech Therapeutics. "In vivo gene editing represents a new generation of therapeutics—offering one-time, durable solutions for chronic and genetic diseases. We are committed to advancing breakthrough gene editing solutions that offer transformative benefits for patients living with severe genetic and cardiovascular diseases. '' About YOLT-101 YOLT-101 is an investigational in vivo base editing therapy designed to be a single-dose treatment to durably reduce blood LDL-C. It is based on YolTech's proprietary adenine base editor, YolBE—specifically hpABE5—which comprises nCas and a novel deaminase evolved from Hafnia paralvei. For delivery, YOLT-101 utilizes YolTech's innovative lipid nanoparticle (LNP) delivery system. Unlike traditional CRISPR/Cas9 systems that rely on DNA double-strand breaks (DSBs), hpABE5 enables precise A•T to G•C base conversion without introducing DSBs, thereby significantly reducing risks of chromosomal abnormalities and off-target effects. YOLT-101 is being evaluated in ongoing investigator-initiated trial (IIT), where it has demonstrated a favorable safety profile and robust LDL-C–lowering effects. For detailed clinical data, please refer to: About Familial Hypercholesterolemia (FH) Familial hypercholesterolemia (FH) is caused by mutations in LDL metabolism-related genes such as LDLR, APOB, and PCSK9. Patients with FH exhibit significantly elevated levels of low-density lipoprotein cholesterol (LDL-C) and a high risk of early-onset atherosclerotic cardiovascular disease (ASCVD). The estimated global prevalence of FH is 1 in 200 to 1 in 250, affecting approximately 34 million individuals worldwide. Current treatment strategies—lifestyle modifications, statins, ezetimibe, PCSK9 inhibitors, lipoprotein apheresis, and even liver transplantation—often fall short in terms of efficacy, tolerability, or patient adherence. This creates a critical unmet need for durable, one-time therapies that can address the root cause of disease. About YolTech YolTech Therapeutics is a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines. Our approach combines innovative gene editing technologies with an advanced lipid nanoparticle (LNP) delivery system, creating a versatile platform designed to address a wide range of serious diseases. Central to our mission is the development of internal capabilities, including end-to-end manufacturing, to ensure the highest standards of quality and scalability. Our lead candidate, targeting ATTR, marks a significant milestone as China's first LNP-mediated in vivo gene editing therapy to enter clinical development. With promising early clinical outcomes, YolTech is also advancing therapies for familial hypercholesterolemia (FH) and primary hyperoxaluria type 1 (PH1). As a company dedicated to transforming the treatment landscape, YolTech continues to push the boundaries of what is possible in gene editing. To learn more, please visit: View original content: SOURCE YolTech Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
